Uncovering the Mechanism of Action of Eylea

This video first explains the pathophysiology of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), focusing on the roles of vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF) in disease progression. Eylea is a dual-action therapy that binds VEGF-A and PlGF with high affinity, effectively blocking all VEGF receptor 1 ligands to reduce inflammation, vascular permeability and angiogenesis. Its extended duration of action offers sustained therapeutic benefits, reducing treatment frequency while improving visual acuity outcomes.